Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 3, 2018
- Accepted in final form February 17, 2019
- First Published April 4, 2019.
Author Disclosures
- Björn Ambrosius, PhD,
- Ralf Gold, MD,
- Andrew Chan, MD and
- Simon Faissner, MD
- Björn Ambrosius, PhD,
NONE
NONE
Commercial, travel grant, 5000? Novartis for AAN 2016
NONE
NONE
NONE
Celgene GmbH, associate Regional Medical Liaison, since September 2018
NONE
NONE
NONE
NONE
NONE
NONE
FORUM Anschubfinanzierung, Medizinische Faktult?t Ruhr Universit?t Bochum, F?rderkennzeichen: F859-15
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ralf Gold, MD,
(1) TEVA Laquinimod DSMB
NONE
Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis
SAGE Journal, Aktuelle Neurologie, Experimental Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Chan, MD and
(1) Almirall (2) Actelion (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva
NONE
(1) Almirall (2) Actelion (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva; travel and speaker honoraria, all for University Research funds
Clinical and Translational Neuroscience (Editorial board) Topic editor, Journal of International medical research
(1) mTOR inhibition as mechanism to increase glucocorticosteroid efficacy
NONE
NONE
NONE
NONE
NONE
NONE
Research support from Biogen, Genzyme, UCB
(1) Schweizer Nationalfonds, Principle investigator, 2 years
NONE
Swiss multiple sclerosis society, Co-PI, 2 years
NONE
NONE
NONE
NONE
NONE
NONE
- Simon Faissner, MD
NONE
NONE
(1) Speaker honoraria from Novartis, not related to the content of this manuscript.
NONE
(1) V. W. Yong, M. Koch, S. Faissner. United States Patent Application No. 62/412,534 filed October 25, 2016, relating to, and entitled: Treatment for Progressive Multiple Sclerosis. (2) V. W. Yong, M. Koch, L. Metz, M. Mishra, S. Faissner. United States Patent Application No. 62/412,555 filed October 25, 2016, relating to, and entitled: Combination therapy with minocycline and hydroxychloroquine for the treatment of multiple sclerosis (MS).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Medical Faculty of Ruhr-University Bochum, FoRUM (F898- 17), not related to this manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (B.A., R.G., S.F.), St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr, Bochum, Germany; and Department of Neurology (A.C.), University Hospital Bern, Bern University, Switzerland.
- Correspondence
Dr. Ambrosius Bjoern.Ambrosius{at}ruhr-uni-bochum.de or Dr. Faissner Simon.Faissner{at}ruhr-uni-bochum.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.